LivaNova PLC (LIVN) fair value analysis

Nasdaq · Updated 2026-09-07

LivaNova PLC is a medical device company that develops and manufactures products for neuromodulation and cardiac surgery applications. The company operates globally with a presence in multiple countries across Europe, North America, and other regions.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, LIVN is trading at within about 10% of estimated fair value.

LIVN currently ranks #76 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $82.46
Sector: Healthcare
12-month range: $50.61–$82.48

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Low
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range

What our data shows for LIVN

Our model validated 17 trailing price-to-earnings windows for LIVN, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $50.61–$82.48.
The 14-day relative strength index sits at a neutral 59.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for LIVN
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent LIVN news

TickrTrends' derived news-sentiment signal for LIVN is currently leaning positive, computed from recent coverage.

GHO Capital appoints Vivid Sehgal as Operating Partner (manilatimes.net, 2026-09-08)
TickrTrends take: GHO Capital's appointment of Vivid Sehgal as Operating Partner represents a strategic move that could influence operational efficiency across its portfolio companies, including LIVN. Given TickrTrends' current assessment that LIVN is fairly valued, investors should monitor whether this leadership addition translates into measurable improvements in operational metrics or cost management that might validate the current valuation range. For a Healthcare sector company trading at fair value, operational enhancements driven by experienced leadership could be a key factor in determining whether the stock offers upside or maintains its current equilibrium.
LivaNova (LIVN) Director Francesco Bianchi Sells 1,650 Shares (gurufocus.com, 2026-09-03)
TickrTrends take: LivaNova operates in the Healthcare sector and is currently assessed as Fairly valued according to TickrTrends analysis. Director share sales such as this transaction warrant monitoring by valuation-focused investors, as insider selling patterns can provide insight into management's confidence levels relative to current market pricing. Given the company's Fairly valued designation, observers should track whether insider transactions continue or shift, as sustained selling activity might suggest management views the stock as appropriately priced or potentially overvalued at current levels.
LIVN Reiterated by Piper Sandler -- Price Target Raised to $90 (gurufocus.com, 2026-09-02)
TickrTrends take: Piper Sandler's reiterated coverage and price target increase to $90 provide external validation for LIVN's current positioning within the Healthcare sector. Given TickrTrends' assessment that the stock is fairly valued at present, investors monitoring valuation metrics should track whether the analyst's elevated price target reflects near-term catalysts or longer-term growth expectations that could shift the fair value perception. The gap between current market levels and the $90 target may indicate whether consensus views LIVN as offering upside potential relative to its intrinsic value fundamentals.

What people are saying

Follow the LIVN conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is LIVN stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), LIVN is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is LIVN's TickrTrends verdict?

LIVN's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does LIVN compare to other Healthcare stocks?

LIVN ranks #76 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is LIVN overbought or oversold?

LIVN's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

LIVN vs ACHC · LIVN vs AZTA · LIVN vs COR · LIVN vs ELV · LIVN vs HCSG